Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinibMCLEAN, Lee Anne; GATHMANN, Insa; CAPDEVILLE, Renaud et al.Clinical cancer research. 2004, Vol 10, Num 1, pp 155-165, issn 1078-0432, 11 p., 1Article

A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in ThailandLEFEVRE, Gilbert; LOOAREESUWAN, Sornchai; TREEPRASERTSUK, Sombat et al.The American journal of tropical medicine and hygiene. 2001, Vol 64, Num 5-6, pp 247-256, issn 0002-9637Article

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and ST1571 (IRIS) trialGUILHOT, François; DRUKER, Brian; LARSON, Richard A et al.Haematologica (Roma). 2009, Vol 94, Num 12, pp 1669-1675, issn 0390-6078, 7 p.Article

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialGUILHOT, François; HUGHES, Timothy P; CORTES, Jorge et al.Haematologica (Roma). 2012, Vol 97, Num 5, pp 731-738, issn 0390-6078, 8 p.Article

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'BRIEN, Stephen G; GUILHOT, Francois; LECHNER, Klaus et al.The New England journal of medicine. 2003, Vol 348, Num 11, pp 994-1004, issn 0028-4793, 11 p.Article

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)DRESSMAN, Marlene A; MALINOWSKI, Rachel; MCLEAN, Lee Anne et al.Clinical cancer research. 2004, Vol 10, Num 7, pp 2265-2271, issn 1078-0432, 7 p.Article

A phase 2 study of imatinib in patients with relapsed or refractory philadelphia chromosome-positive acute lymphoid leukemiasOTTMANN, Oliver G; DRUKER, Brian J; BACCARANI, Michele et al.Blood. 2002, Vol 100, Num 6, pp 1965-1971, issn 0006-4971, 7 p.Article

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia : a subanalysis of the IRIS studyLARSON, Richard A; DRUKER, Brian J; GUILHOT, Francois et al.Blood. 2008, Vol 111, Num 8, pp 4022-4028, issn 0006-4971, 7 p.Article

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cellsDEININGER, Michael W. N; CORTES, Jorge; GAMBACORTI-PASSERINI, Carlo et al.Cancer. 2007, Vol 110, Num 7, pp 1509-1519, issn 0008-543X, 11 p.Article

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHUGHES, Tim P; KAEDA, Jaspal; RADICH, Jerald P et al.The New England journal of medicine. 2003, Vol 349, Num 15, pp 1423-1432, issn 0028-4793, 10 p.Article

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyTALPAZ, Moshe; SILVER, Richard T; HOCHHAUS, Andreas et al.Blood. 2002, Vol 99, Num 6, pp 1928-1937, issn 0006-4971Article

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studySAWYERS, Charles L; HOCHHAUS, Andreas; FISCHER, Thomas et al.Blood. 2002, Vol 99, Num 10, pp 3530-3539, issn 0006-4971Article